MBX Biosciences, Inc. MBX
56.33 USD +2.27 (+4.20%)
At closeNov 10, 2026, 4:00 PM EST
56.33 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
51.52 Day range 58.12
23.07 52-week range 72.64
- YTD
- +78.60%
- 1 year
- +130.01%
News
globenewswire.com MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway 12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for…
accessnewswire.com Microbix Attending & Presenting at IPVS 2026 Presenting Results of Novel Product for Validation & QC of HPV Assays MISSISSAUGA, ON / ACCESS Newswire / October 19, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life…
globenewswire.com MBX Biosciences to Participate in Upcoming November Investor Conferences CARMEL, Ind. and BURLINGTON, Mass.
benzinga.com Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84 Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $84.
benzinga.com Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150 Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $88 to $150.
defenseworld.net MBX Biosciences (NASDAQ:MBX) Shares Climb 4.1% – Time to Buy? Shares of MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) rose 4.1% during trading on Monday. The stock traded as high as $55.93 and last traded at $55.84. 88,613 shares were traded during…
benzinga.com Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
defenseworld.net MBX Biosciences, Inc. $MBX Shares Newly Bought by Bank of America Corp DE Bank of America Corp DE bought a new position in MBX Biosciences, Inc. (NASDAQ: MBX) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission.…
seekingalpha.com MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) MBX Biosciences, Inc. is upgraded to Buy, driven by strong canvuparatide Phase 2 data and a clear path to Phase 3 success in hypoparathyroidism. Canvuparatide's once-weekly dosing and robust efficacy…
seekingalpha.com MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
fool.com Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
fool.com Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
globenewswire.com MBX Biosciences to Participate in Upcoming Investor Conferences CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and…
globenewswire.com MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer CARMEL, Ind. and BURLINGTON, Mass.
defenseworld.net Jupiter Topco LLC Acquires Shares of 10,300 MBX Biosciences, Inc. $MBX Jupiter Topco LLC acquired a new position in shares of MBX Biosciences, Inc. (NASDAQ: MBX) during the undefined quarter, according to the company in its most recent disclosure with the Securities and…
benzinga.com MBX Biosciences Announces First Patient Dosed In Pivotal Phase 3 oPTimize Clinical Trial Evaluating Once-Weekly Canvuparatide For Treatment Of Chronic Hypoparathyroidism Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durableone-year clinical benefitGlobal registrational trial to enroll approximately 160 adults with HP to support
globenewswire.com MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit
benzinga.com JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.
accessnewswire.com Microbix Reports Results for Q3 Fiscal 2026 Q3 Revenues of $4.1 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / August 13, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator,…
benzinga.com Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88 Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $88.- benzinga.com MBX Biosciences Q2 EPS $(0.78) Misses $(0.63) Estimate MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.63) by 23.81 percent. This is a 34.48 percent decrease over losses of…
defenseworld.net MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month High After Analyst Upgrade MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday after Mizuho raised their price target on the stock from $57.00 to $91.00.…
benzinga.com Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91 Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $57 to $91.
defenseworld.net MBX Biosciences (NASDAQ:MBX) Hits New 12-Month High – Here’s Why MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report)'s share price hit a new 52-week high during trading on Friday. The company traded as high as $66.66 and last traded at $61.10, with a volume of…
benzinga.com ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big gainers: PHOE, SG, TRVI, DCBO, ZNTL, GPRE, SLS, FEIM, TRV, BHVN, KOS, BJRI, MBX.
defenseworld.net Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both manufacturing companies, but which is the superior stock? We will compare…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-market session. The company's market cap stands at $1.7 million. Medicus Pharma (NASDAQ:MDCX) stock rose…- benzinga.com MBX Biosciences Appoints Steve Hoerter As Chairman And CEO, Succeeding Kent Hawryluk, With John Smither Named Interim CFO, Effective Immediately MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of…
globenewswire.com MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and…
seekingalpha.com MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy) I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables…
seekingalpha.com MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
benzinga.com MBX Biosciences Highlights Sustained Calcium Control In Rare Disease MBX Biosciences reported one-year canvuparatide data showing sustained calcium control and progress toward a Phase 3 trial.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results. Other stocks declining in pre-market trading.- benzinga.com MBX Biosciences Announces Full Results From 12-Week Avail Phase 2 Trial And New 1-Yr Data From Ongoing OLE Study Of Once-Weekly Canvuparatide In Adult Patients With Chronic Hypoparathyroidism Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trialResults consistent with restoration of systemic PTH activity through serum calcium
benzinga.com Earnings Scheduled For May 14, 2026 
benzinga.com Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70 Barclays analyst Eliana Merle maintains MBX Biosciences (NASDAQ:MBX) with a Overweight and raises the price target from $66 to $70.- benzinga.com Citizens Maintains Market Outperform on MBX Biosciences, Raises Price Target to $86 Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ:MBX) with a Market Outperform and raises the price target from $76 to $86.
benzinga.com Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $70 Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $50 to $70.- benzinga.com MBX Biosciences Announces Multiple Updates On Obesity Portfolio; Preliminary Blinded Phase 1 Data For MBX 4291 Show Pharmacokinetic Profile Supporting Potential For Once-Monthly Dosing And Competitive Weight Loss In First MAD Cohort Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo)MBX 4291 generally well…
- benzinga.com MBX Biosciences Q1 EPS $(0.51) Beats $(0.61) Estimate MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.61) by 16.39 percent. This is a 28.17 percent increase over losses of…
- benzinga.com MBX Biosciences Q4 EPS $(0.49) Beats $(0.68) Estimate MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.68) by 27.84 percent. This is a 4.26 percent decrease over losses of…
- benzinga.com Earnings Scheduled For February 12, 2026
- benzinga.com Barclays Initiates Coverage On MBX Biosciences with Overweight Rating, Announces Price Target of $66 Barclays analyst Eliana Merle initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweight rating and announces Price Target of $66.
- benzinga.com Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $88 Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $77 to $88.
- benzinga.com UBS Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $60 UBS analyst Michael Yee initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and announces Price Target of $60.
benzinga.com Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - benzinga.com Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $50 Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $45 to $50.
- benzinga.com Earnings Scheduled For December 18, 2025
- benzinga.com Goldman Sachs Initiates Coverage On MBX Biosciences with Sell Rating, Announces Price Target of $18 Goldman Sachs analyst Corinne Johnson initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Sell rating and announces Price Target of $18.